Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain. (May 2018)

• Record Type: Journal Article
• Authors: Martí, Edelmira; Segado, Alejandra; Pastor-Galán, Irene; Amat, Paula; Remigia, Maria José; Solano, Carlos; Navarro, Blanca
• Is Part Of: Future cardiology. Volume 14:Number 3(2018)Supplement
• Page Start: 3
• Page End: 8
• Publication Date: 2018-05
• Subjects: atrial fibrillation -- effectiveness -- rivaroxaban -- routine practice -- safety; Cardiology -- Research -- Periodicals; 616.12005
• DOI: 10.2217/fca-2018-0020
• Languages: English
• ISSNs: 1479-6678

Abstract

Aim: To analyze the clinical profile and rates of stroke, major bleeding and intracranial hemorrhage of patients with atrial fibrillation (AF) treated with rivaroxaban in clinical practice.Methods: Retrospective study of AF patients anticoagulated with rivaroxaban in a Healthcare Area of Valencia, Spain. Patients started treatment with rivaroxaban from July 2012 to December 2015.Results: A total of 230 patients (mean age 76.9 ± 9.9 years; CHA2 DS2 -VASc 4.3 ± 1.7; HAS-BLED 1.7 ± 0.9) were included. Rates of stroke, major bleeding and intracranial bleeding were 0.4, 1.9 and 0.5 events per 100 patient-years, respectively.Conclusion: In this cohort of AF patients anticoagulated with rivaroxaban, despite patients being older and having a high thromboembolic risk, rates of stroke, major bleeding and intracranial bleeding were low.